Table 2.
Baseline demographics
| mPAP <21 mmHg (n = 968) | mPAP 21–24 mmHg (n = 689) | mPAP ≥25 mmHg (n = 1272) | Overall (n = 2929) | P-value | |
|---|---|---|---|---|---|
| Age | 60.0 [48.0–71.0]a,b | 65.0 [54.0–73.0]c | 67.0 [57.0–74.0] | 65.0 [53.0–73.0] | <.000001 |
| Gender | |||||
| Female | 665 (68.7%) | 454 (65.9%) | 809 (63.6%) | 1928 (65.8%) | |
| Male | 303 (31.3%)b | 235 (34.1%) | 463 (36.4%) | 1001 (34.2%) | .04164 |
| Ethnicity | |||||
| White | 701 (80.1%) | 521 (81.2%) | 985 (83.8%) | 2207 (82.0%) | |
| Asian | 71 (8.1%) | 54 (8.4%) | 74 (6.3%) | 199 (7.4%) | |
| Black | 51 (5.8%) | 48 (7.5%) | 76 (6.5%) | 175 (6.5%) | |
| Other | 52 (5.9%) | 19 (3.0%) | 41 (3.5%) | 112 (4.2%) | P = NS |
| WHO functional class | |||||
| I | 73 (9.1%) | 23 (3.6%) | 10 (0.8%) | 106 (3.9%) | |
| II | 297 (36.8%) | 205 (32.3%) | 169 (13.6%) | 672 (25.0%) | |
| III | 418 (51.9%) | 390 (61.4%) | 964 (77.6%) | 1773 (66.1%) | |
| IV | 18 (2.2%) | 17 (2.7%) | 100 (8.0%) | 135 (5.0%) | P = NS |
| CAMPHOR | |||||
| Symptoms | 11.0 [6.5–17.0] | 11.0 [6–17.0] | 12.0 [8–17.0] | 12 [7.0–17.0] | .06478 |
| Activity | 9.00 [4–15.0]b | 11.0 [6–16.0]c | 12.0 [7–18.0] | 11.0 [6.0–16.0] | <.000001 |
| QoL | 9.00 [2.25–15.0]b | 8.00 [3–15.0]c | 10.0 [5–16.0] | 9.5 [4.0–16.0] | .00938 |
| emPHasis-10 score | 26.0 [15.0–34.0] | 23.0 [10–30.5]c | 28.0 [16–37.0] | 25.0 [15.0–35.0] | .01711 |
| % of predicted walking distance | 64.8 [45.49–80.42]a,b | 60.2 [39–77.6]c | 45.6 [27–66.4] | 55.9 [33.0–73.7] | <.000001 |
| Borg Dyspnoea scale | 3.00 [2.0–5.0]b | 3.00 [2.0–5.0]c | 4.00 [3.0–5.0] | 4.0 [2.0–5.0] | <.000001 |
For continuous variables expressed in median [IQR]. n and missing values can be found in Supplementary data online, Table S6.
CAMPHOR, Cambridge Pulmonary Hypertension Outcome Review; NS, not significant.
a P-value <.05 between mPAP <21 mmHg and mPAP 21–24 mmHg.
b P-value <.05 between mPAP <21 mmHg and mPAP ≥ 25 mmHg.
c P-value <.05 between mPAP 21–24 mmHg and mPAP ≥ 25 mmHg.